Background: Coronavirus disease 2019 (Covid19) occurs after exposure to severe acute respiratory syndrome coronavirus 2 (SARSCoV2). For persons who are at high risk of exposure, the standard of care is personal protection from getting infected. Whether Ayurvedic rasayana drug like Chyawanprash can prevent symptomatic infection in frontline health care workers is unknown. Objective: To evaluate the effect of the combination of Chyawanprash and Standard Preventive Regimen compared to the use of Standard Preventive Regimen alone on the proportion of RT-PCR confirmed COVID 19 infections among frontline healthcare workers (HCWs). Methods: An open label randomized controlled trial was conducted in the HCWs between 25 to 60 years age currently working in an environment with chance of direct exposure to COVID 19 cases. The interventions to be compared in this trial were Standard Preventive Regimen as per institutional guidelines and based on their roles (Group I) and Ayurvedic Intervention viz., Chyawanprash 12 g twice for 30 days from day of randomization plus Standard Preventive Regimen (Group II). The incidence of RT PCR confirmed COVID19 cases in both groups, was the primary outcome measure. Evaluation of the safety of the study drug (by any statistically significant change in various biochemical and hematological parameters and occurrence of any adverse drug reactions); incidence of any other infective diseases (bacterial / viral / fungal / etc.) like upper respiratory tract illness during the study period and any change in the immunoglobulins like IgG, IgM and IgE and inflammatory markers like TNF alpha, IL6 and IL10 were the secondary outcome measures. Results: Out of 193 participants who completed the study, no participant in both groups was COVID 19 positive at the end of one month. In post intervention follow up, 4 subjects in Group I and 2 subjects in Group II were COVID 19 positive. No adverse drug reaction or any serious adverse event was reported during the study. No clinically significant change in the safety parameters was observed before and after the study. Statistically significant rise in Serum IgG level was seen in Group II but other inflammatory and immune markers did not show statistically significant difference. Conclusion: Chyawanprash was well tolerated by all the participants in the intervention group but to prove its adaptogenic effect and efficacy as an add-on to the standard care in preventing the occurrence of COVID 19, clinical trial for longer duration with larger sample size is needed. Trial registration: Clinical Trials Registry of India vide CTRI/2020/05/025275 dated 20/05/2020 Date of IEC approval: 19.5.2020 Keywords: Adaptogen, Ayurveda, Health personnel, Prophylaxis, Rasayana, SARS CoV 2

Visible light mediated, an eco-friendlier synthetic protocol for dihydropyrano[2,3-c]pyrazoles via catalyst-free and solvent-free conditions at room temperature.

No abstract

Introduction:Cervical spondylosis is a general term for age-related wear and tear affecting the spinal disks in the neck. Keeping in view the increasing incidence of this problem in modern society a study was conducted with following.Aims and Objectives:The aim of the following study is to assess the efficacy of Grīvā Vasti in the management of cervical spondylosis.Materials and Methods:The study was conducted on 10 clinically, pathologically, and radiologically diagnosed patients of cervical spondylosis, selected from outpatient department/In -patient department wing of P.G. Department of Kāya Chikitsā, N.I.A., Jaipur, satisfying the inclusion criteria. Patients were treated with Grīvā Vasti with Daśamūla Tailam for 35-45 min duration, for 14 days. Assessments were performed with regard to neck disability index before and after treatment.Statistical Analysis:Statistical analysis was done with the help of Instat GraphPad 3 using Wilcoxon matched-pairs signed ranks test.Result:Relief in neck disability index was 65.70%, which was statistically significant (P < 0.01).Conclusion:Result indicates that Grīvā Vasti is an effective treatment in cervical spondylosis.

No abstract